Curis (CRIS) Stock Price Down 5.3%

Curis, Inc. (NASDAQ:CRIS) dropped 5.3% on Wednesday . The company traded as low as $0.71 and last traded at $0.72. Approximately 2,245,796 shares changed hands during mid-day trading, an increase of 32% from the average daily volume of 1,698,782 shares. The stock had previously closed at $0.76.

CRIS has been the subject of a number of research analyst reports. Guggenheim initiated coverage on Curis in a report on Monday, October 23rd. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research downgraded Curis from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Three equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $6.50.

The firm has a market capitalization of $118.07, a P/E ratio of -1.73 and a beta of 1.63. The company has a quick ratio of 5.15, a current ratio of 5.15 and a debt-to-equity ratio of 1.24.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). The company had revenue of $2.44 million for the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. Curis’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.21) earnings per share. equities analysts predict that Curis, Inc. will post -0.41 earnings per share for the current fiscal year.

In related news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of $1.06 per share, for a total transaction of $53,000.00. Following the purchase, the chief executive officer now directly owns 115,890 shares in the company, valued at $122,843.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 4.07% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of CRIS. FNY Partners Fund LP boosted its position in Curis by 350.0% during the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 52,500 shares during the period. OxFORD Asset Management LLP acquired a new position in Curis during the 2nd quarter worth $115,000. Voya Investment Management LLC boosted its position in Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 12,207 shares during the period. Alliancebernstein L.P. boosted its position in Curis by 338.7% during the 2nd quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 64,700 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in Curis by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 8,102 shares during the period. Hedge funds and other institutional investors own 55.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Curis (CRIS) Stock Price Down 5.3%” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply